147 related articles for article (PubMed ID: 22427466)
1. [Changes in psychosocial symptoms of opiate users over six months with buprenorphine/naloxone substitution therapy].
Petke Z; Csorba J; Meszaros J; Vingender I; Farkas J; Demetrovics Z; Kovacs Z; Menczel Z; Pataki Z; Simor P; Havasi A; Melles K; Marvanykovi F; Racz J
Neuropsychopharmacol Hung; 2012 Mar; 14(1):7-17. PubMed ID: 22427466
[TBL] [Abstract][Full Text] [Related]
2. Early experience with Suboxone maintenance therapy in Hungary.
Demetrovics Z; Farkas J; Csorba J; Németh A; Mervó B; Szemelyácz J; Fleischmann E; Kassai-Farkas A; Petke Z; Oroján T; Rózsa S; Rigó P; Funk S; Kapitány M; Kollár A; Rácz J
Neuropsychopharmacol Hung; 2009 Dec; 11(4):249-57. PubMed ID: 20150662
[TBL] [Abstract][Full Text] [Related]
3. Use and misuse of opioid replacement therapies: a Queensland study.
Smirnov A; Kemp R
Subst Use Misuse; 2012 Jan; 47(1):78-85. PubMed ID: 22216993
[TBL] [Abstract][Full Text] [Related]
4. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone.
Fudala PJ; Bridge TP; Herbert S; Williford WO; Chiang CN; Jones K; Collins J; Raisch D; Casadonte P; Goldsmith RJ; Ling W; Malkerneker U; McNicholas L; Renner J; Stine S; Tusel D;
N Engl J Med; 2003 Sep; 349(10):949-58. PubMed ID: 12954743
[TBL] [Abstract][Full Text] [Related]
5. Clinical profile of responders to buprenorphine as a substitution treatment in heroin addicts: results of a multicenter study of 73 patients.
Poirier MF; Laqueille X; Jalfre V; Willard D; Bourdel MC; Fermanian J; Olié JP
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):267-72. PubMed ID: 14751421
[TBL] [Abstract][Full Text] [Related]
6. Group medication management for buprenorphine/naloxone in opioid-dependent veterans.
Berger R; Pulido C; Lacro J; Groban S; Robinson S
J Addict Med; 2014; 8(6):415-20. PubMed ID: 25275875
[TBL] [Abstract][Full Text] [Related]
7. Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey.
Curcio F; Franco T; Topa M; Baldassarre C;
Eur Rev Med Pharmacol Sci; 2011 Aug; 15(8):871-4. PubMed ID: 21845796
[TBL] [Abstract][Full Text] [Related]
8. Modeling longitudinal changes in buprenorphine treatment outcome for opioid dependence.
Saleh MI
Pharmacopsychiatry; 2014 Nov; 47(7):251-8. PubMed ID: 25321188
[TBL] [Abstract][Full Text] [Related]
9. Safety, effectiveness and tolerance of buprenorphine-naloxone in the treatment of opioid dependence: results from a nationwide non-interventional study in routine care.
Apelt SM; Scherbaum N; Gölz J; Backmund M; Soyka M
Pharmacopsychiatry; 2013 May; 46(3):94-107. PubMed ID: 23293011
[TBL] [Abstract][Full Text] [Related]
10. Time to include buprenorphine-naloxone combination in the WHO Model List of Essential Medicines.
Balhara YP
J Opioid Manag; 2013; 9(4):237. PubMed ID: 24380101
[No Abstract] [Full Text] [Related]
11. Sex differences in opioid use and medical issues during buprenorphine/naloxone treatment.
Barbosa-Leiker C; McPherson S; Layton ME; Burduli E; Roll JM; Ling W
Am J Drug Alcohol Abuse; 2018; 44(4):488-496. PubMed ID: 29672167
[TBL] [Abstract][Full Text] [Related]
12. A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic.
Matson SC; Hobson G; Abdel-Rasoul M; Bonny AE
J Addict Med; 2014; 8(3):176-82. PubMed ID: 24695018
[TBL] [Abstract][Full Text] [Related]
13. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings.
Mintzer IL; Eisenberg M; Terra M; MacVane C; Himmelstein DU; Woolhandler S
Ann Fam Med; 2007; 5(2):146-50. PubMed ID: 17389539
[TBL] [Abstract][Full Text] [Related]
14. Evidence of validity and reliability of the Opiate Dosage Adequacy Scale (ODAS) in a sample of heroin addicted patients in buprenorphine/naloxone maintenance treatment.
González-Saiz F; Lozano Rojas O; Trujols J; Alcaraz S; Siñol N; Pérez de Los Cobos J;
Drug Alcohol Depend; 2018 Feb; 183():127-133. PubMed ID: 29247974
[TBL] [Abstract][Full Text] [Related]
15. Buprenorphine + naloxone: new combination. Opiate dependence: no proof of reduced risk of self-administered injection.
Prescrire Int; 2007 Dec; 16(92):232-5. PubMed ID: 18087797
[TBL] [Abstract][Full Text] [Related]
16. Medically assisted recovery from opiate dependence within the context of the UK drug strategy: methadone and Suboxone (buprenorphine-naloxone) patients compared.
McKeganey N; Russell C; Cockayne L
J Subst Abuse Treat; 2013 Jan; 44(1):97-102. PubMed ID: 22703715
[TBL] [Abstract][Full Text] [Related]
17. Medically assisted treatment for opiate addiction--suboxone method as prevention of social exclusion of youth--Tuzla model.
Hasanović M; Pajević I; Kuldija A; Delić A
Psychiatr Danub; 2012 Oct; 24 Suppl 3():S398-404. PubMed ID: 23114824
[TBL] [Abstract][Full Text] [Related]
18. Buprenorphine and naloxone interactions in opiate-dependent volunteers.
Mendelson J; Jones RT; Fernandez I; Welm S; Melby AK; Baggott MJ
Clin Pharmacol Ther; 1996 Jul; 60(1):105-14. PubMed ID: 8689806
[TBL] [Abstract][Full Text] [Related]
19. Buprenorphine in the treatment of opiate dependence.
Wesson DR; Smith DE
J Psychoactive Drugs; 2010 Jun; 42(2):161-75. PubMed ID: 20648912
[TBL] [Abstract][Full Text] [Related]
20. Suboxone misuse along the opiate maintenance treatment pathway.
Furst RT
J Addict Dis; 2013; 32(1):53-67. PubMed ID: 23480248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
